Related Experiment Video
Updated: Oct 18, 2025
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.1K
An update on adalimumab for pyoderma gangrenosum.
1Department of Dermatology, Fukushima Medical University, Fukushima, Japan. toyamade@fmu.ac.jp.
Drugs of Today (Barcelona, Spain : 1998)
|September 29, 2021
Summary
Adalimumab shows promise for treating pyoderma gangrenosum, a chronic skin ulcer disease. In a study of Japanese patients, adalimumab led to significant ulcer healing and symptom improvement within 26 weeks.
Area of Science:
- Dermatology
- Immunology
- Clinical Medicine
Background:
- Pyoderma gangrenosum (PG) is a rare, chronic inflammatory skin disease characterized by painful ulcers.
- Current treatments like oral steroids and cyclosporine have limitations, indicating a need for novel therapies.
Purpose of the Study:
- To evaluate the efficacy and safety of adalimumab in Japanese patients with active pyoderma gangrenosum ulcers.
Main Methods:
- An open-label, multicenter study involving 22 Japanese patients with PG.
- Patients received adalimumab treatment for an initial 26 weeks, followed by a 26-week extension period.
Main Results:
- Complete skin re-epithelialization (PGAR 100) was achieved by 54.5% of patients by week 26.
- Significant reduction in ulcer area (-63.8%) and improvement in physician global assessment were observed.
- Adalimumab was generally well-tolerated, with infections being the most common adverse event.
Conclusions:
- Adalimumab demonstrates significant efficacy in promoting ulcer healing and improving clinical outcomes for Japanese patients with pyoderma gangrenosum.
- The drug appears to be a safe and effective treatment option for this challenging dermatological condition.
Keywords:
AdalimumabDermatologic disordersInflammatory skin diseasesPyoderma gangrenosumTumor necrosis factor (TNF) inhibitorsMore Related Videos
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
287
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
287
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
259
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
259
01:29Inflammatory Bowel Disease IV: Pharmacological Management
242
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
242
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
240
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
240
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
75
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
75
01:29Drugs for Treatment of Ulcerative Colitis in IBD
269
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
269